Articles tagged with Cancer Patients
Researchers analyzed data on 553 patients treated with imatinib, finding that complete cytogenetic response significantly impacted long-term outcome. Patients with low Philadelphia chromosome positivity had higher chances of achieving a complete response.
Researchers at Moffitt will evaluate vaccine therapy INGN 225 in a phase I/II study for patients with advanced breast cancer. The treatment has shown promising results in preclinical trials, with 100% protection against tumors achieved when dendritic cells were activated.
A study by Michigan Medicine found that seeking a second opinion for breast cancer may significantly alter diagnosis and treatment plans. The research, led by Dr. Amy Rochester Guest, suggests that patients with complex cases or those who are diagnosed with both breasts affected benefit most from consulting specialized teams.
A new cryoablation technique has shown promising results in killing most small malignant breast cancers, with seven out of nine patients experiencing complete tumor necrosis. The technique also showed no cosmetic changes to the breast's appearance and may be a viable option for women with early-stage disease.
Researchers found that calcium supplements reduced the risk of colorectal cancer recurrence only among individuals with baseline vitamin D levels above the median. Serum vitamin D levels were also associated with reduced adenoma recurrence among individuals taking calcium supplements.
A new CT scan technique called multi-detector CT urography (MDCTU) has been shown to detect various urinary system problems, including bladder cancer, kidney stones, and cysts. The technique is more accurate than traditional methods and may be beneficial for high-risk patients.
The partnership aims to address unequal burden of cancer on minority communities by providing access to clinical trials and strengthening cancer research programs. The collaboration will enhance cancer treatment capability and produce healthier outcomes for patients in South Central Los Angeles.
A clinical study found that molecular markers can predict which head and neck cancer patients will respond better to radiotherapy. The study identified two tumor profiles with different clinical outcomes, one with a high response rate of 67% and another with a poor response rate of 37%.
Researchers develop protein profiles to classify gliomas and predict aggressiveness with high accuracy. The 'molecular fingerprint' can help tailor treatment decisions for patients, distinguishing between aggressive and less aggressive tumors.
Researchers found that black patients undergoing surgery had a median survival time 1.8 years less than white patients, with disparities smaller among radiation therapy and non-aggressive therapy groups. The study suggests genetic and environmental factors may contribute to these racial disparities in prostate cancer treatment outcomes.
Black patients with locally advanced prostate cancer may have had less access to specialized radiation therapy, which is preferred over surgery. Postmenopausal women who consume moderate amounts of alcohol may be at an increased risk for cancer due to increased blood serum levels of the fat hormone leptin.
A Phase I study for non-small cell lung cancer used stereotactic radioablation, increasing radiation doses without prohibitive toxicity. 87% of patients showed positive tumor response, with no local recurrence at the highest dose levels.
The University of Pittsburgh will focus on clinical trials to test treatment efficacy and tolerance in older cancer patients, while also addressing behavioral and social issues faced by the elderly. The project aims to better understand the needs and concerns of older adults with cancer.
The UCI Cancer Center is one of six institutions nationwide chosen to conduct early-phase clinical trials testing cancer prevention agents. The center will receive over $2.2 million initially, with a focus on assessing the potential of various substances in preventing cancer recurrence.
Scientists at Memorial Sloan-Kettering Cancer Center discovered that the amount of PTEN protein produced affects prostate cancer progression. Mouse models showed varying levels of PTEN protein led to aggressive or benign tumors, suggesting novel clinical strategies for diagnosis, treatment, and prevention.
Brain cancer patients undergoing radiation therapy are at risk of life-threatening infections due to suppressed immune systems. Researchers found that monitoring immune cell counts and administering prophylactic antibiotics can prevent these side effects, with no patient developing pneumonia or other serious infections in the study.
A multicentre trial involving 351 patients found that anaemia treatment with epoetin beta did not improve cancer control or survival rates. Instead, patients receiving epoetin beta had a 60% better chance of progression-free survival compared to those given placebo.
A multi-center study led by Fox Chase Cancer Center oncologist aims to develop an interactive internet-based tool to assess patient values and information needs, providing education on cancer treatment and communication skills training. The goal is to improve doctor-patient communication and patient satisfaction.
A study published in the American Journal of Managed Care found that guideline-based cancer pain management offers effective pain relief in 80% of patients compared to 30% effectiveness for non-specialty providers. The targeted approach ensures a pre-determined treatment plan, reducing variability and increasing patient outcomes.
Researchers found that specific variants of dopamine transporter and receptor genes associated with higher dopamine levels in the brain facilitated smoking cessation. This study highlights the importance of genetic investigations beyond single gene effects.
A study found that physicians have distinct approaches to explaining clinical trials, which can impact patient enrollment. The research suggests that understanding these differences is crucial for improving doctor-patient interactions and overall care.
The EU's new clinical trial directive may hinder international collaborations, leading to delays in cancer treatment development. This could result in patients being deprived of life-saving treatments, as the effectiveness of new drugs would be determined solely by pharmaceutical industry-sponsored research.
In Sweden, rectal cancer patients have seen a dramatic improvement in five-year survival rates, jumping from 50% to 60%, thanks to changes in hospital practice and quality assurance measures.
A large-scale clinical study by Nordic collaboration has provided new insights into the effects of chemotherapy in colorectal cancer. The analysis demonstrated that among 2,223 patients, those given chemotherapy as part of routine care had a five-year survival rate of 56%, compared to 49% for those treated by surgery alone.
A 57-year study found that hereditary retinoblastoma patients have a significantly higher risk of developing a second primary cancer, with an increased incidence of melanomas and sarcomas. The risk is independent of radiotherapy treatment.
A new coalition of cancer patients is working to promote better treatment, care, and research across Europe. The group hopes to influence European health policymaking and ensure access to high-quality screening, treatment, and care for all cancer patients.
Researchers identify key genes involved in cancer development, including BRAF, and develop targeted drugs to combat the disease. A new approach to cancer treatment is being explored by targeting mutated genes, offering new hope for more efficient treatments.
The European Cancer Patient Coalition is hindered by language barriers, with fewer than 50% of Europeans speaking a second language, including English. Digital divide also persists, with varying internet access across countries, affecting the coalition's ability to operate effectively.
Researchers have made significant progress towards a vaccine for pancreatic cancer, with one patient out of ten remaining disease-free after five years and two others surviving over two years. While the study's findings are promising, caution is advised due to the small sample size and potential biases in the selection process.
Breast cancer patients participating in an online support group experienced improved well-being and empowerment through sharing personal experiences, asking for advice, and expressing emotions. The study highlights the importance of internet access for social support and low-income groups.
A new study found that a rapid increase in the incidence of esophageal and gastric cardia adenocarcinomas is linked to modifiable risk factors such as smoking, being overweight, and gastroesophageal reflux. High serum levels of vitamin E are associated with reduced risk of upper gastrointestinal cancers.
Patients who traveled farther for cancer treatment had improved overall and progression-free survival rates, suggesting that access to information and resources plays a crucial role in cancer outcomes. The study's findings highlight the importance of considering travel distance as a potential factor in phase II clinical trial results.
Patients who traveled at least 15 miles for care had a one-third lower risk of dying during the trial and follow-up period compared to those living closer. The study found that patients with higher incomes, more education, and a supportive social network tended to fare better in terms of survival rates.
Researchers have developed a program to train cancer registrars to track patients' comorbidities, increasing the accuracy of cancer profiles and treatment outcomes. The method is easy for registrars to learn and has shown significant improvements in patient care.
A new study has found that the protein EZH2 is linked to aggressive and deadly breast tumors, with higher levels corresponding to worse patient outcomes. The discovery may lead to a new test for determining breast cancer prognosis more precisely.
Researchers found that wrist bands with acupressure or stimulation applied to an acupuncture point on the wrist reduced nausea in breast cancer patients by 15% compared to no band. Patients who expected the bands to ease their nausea experienced even greater relief, reporting a 25% decrease in nausea severity.
Two new studies found that elderly lung cancer patients benefit equally from aggressive chemotherapy and radiation treatment, contradicting common assumptions. Fit elderly patients should be fully briefed on treatment options, including potential risks and benefits. The studies suggest presenting the full range of treatment options to ...
A new study reveals that patients who received neoadjuvant chemotherapy lived an average of 31 months longer than those treated with surgery alone. The combination therapy showed a 66% greater chance of surviving bladder cancer.
A new nomogram model predicts prostate cancer likelihood in men with PSA levels below 10 ng/ml, helping to reduce unnecessary biopsies. The model identifies four independent risk factors for positive biopsy results and provides a score to calculate the likelihood of cancer presence.
A recent study found that symptoms of depression are a consistent predictor of shortened survival in cancer patients. After accounting for other factors, researchers discovered that depressive symptoms were the most significant psychological indicator of poor outcomes.
A new test method aims to predict which early-stage cancer patients are at high risk for relapse, allowing for more precise treatment decisions. By analyzing apoptosis proteins in patient tumors, researchers hope to identify molecular and genetic signatures that indicate the likelihood of cancer recurrence.
Researchers have developed molecular markers that can predict radiation-induced late toxicity and disease recurrence in prostate cancer. The study used apoptosis assays to evaluate cell death induced by radiation, revealing correlations between lymphocyte apoptosis and toxicities.
Researchers at Wake Forest University Baptist Medical Center have found that oxaliplatin can effectively treat human cancers resistant to other platinum-based therapies. The drug works differently than cisplatin and shows promise in combination with radiation therapy for patients with earlier stages of rectal cancer.
Researchers used blood samples to analyze protein patterns and determine if biopsies were necessary. The test showed a sensitivity of 100% and specificity of 67%, suggesting it could save over 50% of biopsies. The study's results may lead to more accurate cancer detection and tailored therapy for individual patients.
The Lombardi Cancer Center will investigate how drinking affects breast cancer risk, focusing on estrogens, free radicals, and gene mutations. The center aims to improve public health recommendations and inform individual lifestyle choices.
A national study found that 43% of patients reported nausea on the day of treatment, and 73% experienced nausea one or more days later. Delayed nausea is a significant problem, affecting twice as many patients who felt ill in the following days compared to those who felt queasy initially.
Researchers found a slightly increased risk of ovarian cancer in women with endometriosis, with a half-life increase and higher risks for younger women. In contrast, the risk of cervical cancer was reduced by roughly a third. Further investigation is needed to understand the connection between endometriosis and cancer.
Researchers found that the p53 gene plays a crucial role in distinguishing which lung cancer patients are most likely to survive four years or more. The study identified a sub-group of early-stage lung cancer patients without p53 mutations who had a significantly higher survival rate, providing hope for a new treatment approach.
A phase II multicenter collaborative study found that Velcade significantly reduced disease in 67% of patients with advanced multiple myeloma, with some achieving complete or near-complete responses. The drug has shown great potential to improve patient outcomes in this incurable disease.
Researchers at UW-Madison will enhance the Comprehensive Health Enhancement Support System (CHESS) with new functions tailored to individual needs. The center's projects aim to improve patient outcomes, quality of life, and cost-effectiveness in cancer communication systems.
The Society of Nuclear Medicine has announced an image that represents a significant advance in achieving high throughput in PET scanning without sacrificing quality. The image showcases technology such as 3D-LSO PET/CT, which could decrease whole-body scan duration substantially, benefiting nuclear medicine professionals and patients.
Researchers have developed a new treatment strategy that combines chemo-radiation and surgery to prevent recurrence of rectal cancer. The study, conducted by Professor Andres Cervantes' team, demonstrated excellent results with no local relapse after two years.
A study suggests that extending screening intervals could reduce lead-time bias and overdetection rates associated with prostate cancer screenings. The research estimates a potential 60-90% increase in prostate cancer incidence, highlighting the need to weigh benefits against risks.
Researchers found that AIDS-related lymphomas responding well to chemotherapy have high levels of proteins indicating rapid growth and multidrug resistance. The study also showed that suspending antiretroviral therapy during lymphoma treatment is safe and allows for high overall survival.
Drs. Chang and Moore were awarded the Mott Prize for their discovery of KSHV, a virus linked to Kaposi's sarcoma, the most common malignancy in AIDS patients. Their work has opened new areas in cancer research and will continue to use innovative techniques to understand KSHV's impact on cancer.
Researchers found NRAS mutations in 95% of primary hereditary melanomas, but only 10% of sporadic melanomas. The study suggests a link between UV light exposure and the activation of NRAS mutations in early stages of melanoma development.
Researchers at Michigan Medicine have identified 158 genes specific to pancreatic cancer in a new study, providing a more accurate accounting of the disease's molecular makeup. The team hopes to use this knowledge to develop new diagnostic tests and treatments tailored to individual patients.
Researchers at The Wistar Institute developed DNA arrays to accurately diagnose Sezary syndrome, a leukemic variant of cutaneous T-cell lymphoma. The technology identified genetic markers that can predict patient survival and identify potential drug targets.
A study found that examining lymph nodes in women with early-stage uterine cancer can prevent unnecessary radiation therapy and improve treatment outcomes. The researchers analyzed data from 144 women diagnosed with grade 1 endometrial cancer, finding that lymph node removal saved patients from unneeded radiation therapy in 22 cases.
The Ireland Cancer Center's Phase I and II trials report remarkable responses to new therapies for skin lymphoma, multiple myeloma, and solid tumors. These innovative treatments overcome common complications like kidney and liver damage, offering hope to patients with limited treatment options.